525 related articles for article (PubMed ID: 22847671)
1. Pentraxin 3 (PTX3) inhibits plasma cell/stromal cell cross-talk in the bone marrow of multiple myeloma patients.
Basile A; Moschetta M; Ditonno P; Ria R; Marech I; De Luisi A; Berardi S; Frassanito MA; Angelucci E; Derudas D; Specchia G; Curci P; Pavone V; Rossini B; Ribatti D; Bottazzi B; Mantovani A; Presta M; Dammacco F; Vacca A
J Pathol; 2013 Jan; 229(1):87-98. PubMed ID: 22847671
[TBL] [Abstract][Full Text] [Related]
2. Pentraxin 3 inhibits fibroblast growth factor 2-dependent activation of smooth muscle cells in vitro and neointima formation in vivo.
Camozzi M; Zacchigna S; Rusnati M; Coltrini D; Ramirez-Correa G; Bottazzi B; Mantovani A; Giacca M; Presta M
Arterioscler Thromb Vasc Biol; 2005 Sep; 25(9):1837-42. PubMed ID: 16020751
[TBL] [Abstract][Full Text] [Related]
3. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.
Alessi P; Leali D; Camozzi M; Cantelmo A; Albini A; Presta M
Eur Cytokine Netw; 2009 Dec; 20(4):225-34. PubMed ID: 20167562
[TBL] [Abstract][Full Text] [Related]
4. A HGF/cMET autocrine loop is operative in multiple myeloma bone marrow endothelial cells and may represent a novel therapeutic target.
Ferrucci A; Moschetta M; Frassanito MA; Berardi S; Catacchio I; Ria R; Racanelli V; Caivano A; Solimando AG; Vergara D; Maffia M; Latorre D; Rizzello A; Zito A; Ditonno P; Maiorano E; Ribatti D; Vacca A
Clin Cancer Res; 2014 Nov; 20(22):5796-807. PubMed ID: 25212607
[TBL] [Abstract][Full Text] [Related]
5. miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF.
Sun CY; She XM; Qin Y; Chu ZB; Chen L; Ai LS; Zhang L; Hu Y
Carcinogenesis; 2013 Feb; 34(2):426-35. PubMed ID: 23104180
[TBL] [Abstract][Full Text] [Related]
6. Endothelial cell-derived pentraxin 3 limits the vasoreparative therapeutic potential of circulating angiogenic cells.
O'Neill CL; Guduric-Fuchs J; Chambers SE; O'Doherty M; Bottazzi B; Stitt AW; Medina RJ
Cardiovasc Res; 2016 Dec; 112(3):677-688. PubMed ID: 27659714
[TBL] [Abstract][Full Text] [Related]
7. Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma.
Paiva B; Pérez-Andrés M; Vídriales MB; Almeida J; de las Heras N; Mateos MV; López-Corral L; Gutiérrez NC; Blanco J; Oriol A; Hernández MT; de Arriba F; de Coca AG; Terol MJ; de la Rubia J; González Y; Martín A; Sureda A; Schmidt-Hieber M; Schmitz A; Johnsen HE; Lahuerta JJ; Bladé J; San-Miguel JF; Orfao A; ;
Leukemia; 2011 Apr; 25(4):697-706. PubMed ID: 21252988
[TBL] [Abstract][Full Text] [Related]
8. Angiogenic activity of mesenchymal stem cells in multiple myeloma.
Wang X; Zhang Z; Yao C
Cancer Invest; 2011 Jan; 29(1):37-41. PubMed ID: 21166497
[TBL] [Abstract][Full Text] [Related]
9. Selective recognition of fibroblast growth factor-2 by the long pentraxin PTX3 inhibits angiogenesis.
Rusnati M; Camozzi M; Moroni E; Bottazzi B; Peri G; Indraccolo S; Amadori A; Mantovani A; Presta M
Blood; 2004 Jul; 104(1):92-9. PubMed ID: 15031207
[TBL] [Abstract][Full Text] [Related]
10. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms.
Nefedova Y; Landowski TH; Dalton WS
Leukemia; 2003 Jun; 17(6):1175-82. PubMed ID: 12764386
[TBL] [Abstract][Full Text] [Related]
11. Role of interleukin 16 in multiple myeloma.
Atanackovic D; Hildebrandt Y; Templin J; Cao Y; Keller C; Panse J; Meyer S; Reinhard H; Bartels K; Lajmi N; Sezer O; Zander AR; Marx AH; Uhlig R; Zustin J; Bokemeyer C; Kröger N
J Natl Cancer Inst; 2012 Jul; 104(13):1005-20. PubMed ID: 22745469
[TBL] [Abstract][Full Text] [Related]
12. Long pentraxin 3/tumor necrosis factor-stimulated gene-6 interaction: a biological rheostat for fibroblast growth factor 2-mediated angiogenesis.
Leali D; Inforzato A; Ronca R; Bianchi R; Belleri M; Coltrini D; Di Salle E; Sironi M; Norata GD; Bottazzi B; Garlanda C; Day AJ; Presta M
Arterioscler Thromb Vasc Biol; 2012 Mar; 32(3):696-703. PubMed ID: 22267482
[TBL] [Abstract][Full Text] [Related]
13. Role of erythropoietin in the angiogenic activity of bone marrow endothelial cells of MGUS and multiple myeloma patients.
Lamanuzzi A; Saltarella I; Ferrucci A; Ria R; Ruggieri S; Racanelli V; Rao L; Annese T; Nico B; Vacca A; Ribatti D
Oncotarget; 2016 Mar; 7(12):14510-21. PubMed ID: 26919105
[TBL] [Abstract][Full Text] [Related]
14. Modulation of the angiogenic phenotype of normal and systemic sclerosis endothelial cells by gain-loss of function of pentraxin 3 and matrix metalloproteinase 12.
Margheri F; Serratì S; Lapucci A; Chillà A; Bazzichi L; Bombardieri S; Kahaleh B; Calorini L; Bianchini F; Fibbi G; Del Rosso M
Arthritis Rheum; 2010 Aug; 62(8):2488-98. PubMed ID: 20506099
[TBL] [Abstract][Full Text] [Related]
15. Decorin is down-regulated in multiple myeloma and MGUS bone marrow plasma and inhibits HGF-induced myeloma plasma cell viability and migration.
Kristensen IB; Pedersen L; Rø TB; Christensen JH; Lyng MB; Rasmussen LM; Ditzel HJ; Børset M; Abildgaard N
Eur J Haematol; 2013 Sep; 91(3):196-200. PubMed ID: 23607294
[TBL] [Abstract][Full Text] [Related]
16. Long pentraxin-3 as an epithelial-stromal fibroblast growth factor-targeting inhibitor in prostate cancer.
Ronca R; Alessi P; Coltrini D; Di Salle E; Giacomini A; Leali D; Corsini M; Belleri M; Tobia C; Garlanda C; Bonomi E; Tardanico R; Vermi W; Presta M
J Pathol; 2013 Jun; 230(2):228-38. PubMed ID: 23424081
[TBL] [Abstract][Full Text] [Related]
17. Bone marrow fibroblasts overexpress miR-27b and miR-214 in step with multiple myeloma progression, dependent on tumour cell-derived exosomes.
Frassanito MA; Desantis V; Di Marzo L; Craparotta I; Beltrame L; Marchini S; Annese T; Visino F; Arciuli M; Saltarella I; Lamanuzzi A; Solimando AG; Nico B; De Angelis M; Racanelli V; Mariggiò MA; Chiacchio R; Pizzuti M; Gallone A; Fumarulo R; D'Incalci M; Vacca A
J Pathol; 2019 Feb; 247(2):241-253. PubMed ID: 30357841
[TBL] [Abstract][Full Text] [Related]
18. Hepatocyte growth factor pathway upregulation in the bone marrow microenvironment in multiple myeloma is associated with lytic bone disease.
Kristensen IB; Christensen JH; Lyng MB; Møller MB; Pedersen L; Rasmussen LM; Ditzel HJ; Abildgaard N
Br J Haematol; 2013 May; 161(3):373-82. PubMed ID: 23431957
[TBL] [Abstract][Full Text] [Related]
19. Four proteins governing overangiogenic endothelial cell phenotype in patients with multiple myeloma are plausible therapeutic targets.
Berardi S; Caivano A; Ria R; Nico B; Savino R; Terracciano R; De Tullio G; Ferrucci A; De Luisi A; Moschetta M; Mangialardi G; Catacchio I; Basile A; Guarini A; Zito A; Ditonno P; Musto P; Dammacco F; Ribatti D; Vacca A
Oncogene; 2012 May; 31(18):2258-69. PubMed ID: 21963844
[TBL] [Abstract][Full Text] [Related]
20. Immature dendritic cells from patients with multiple myeloma are prone to osteoclast differentiation in vitro.
Tucci M; Ciavarella S; Strippoli S; Brunetti O; Dammacco F; Silvestris F
Exp Hematol; 2011 Jul; 39(7):773-83.e1. PubMed ID: 21569821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
